Rice Hall James & Associates LLC Buys Shares of 28,562 ANI Pharmaceuticals, Inc. $ANIP

Rice Hall James & Associates LLC bought a new position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) in the second quarter, Holdings Channel reports. The institutional investor bought 28,562 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,364,000.

Other institutional investors have also modified their holdings of the company. Vanguard Group Inc. boosted its position in shares of ANI Pharmaceuticals by 2.2% during the 4th quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company’s stock valued at $103,022,000 after acquiring an additional 27,598 shares during the last quarter. State Street Corp increased its position in ANI Pharmaceuticals by 2.2% during the fourth quarter. State Street Corp now owns 727,204 shares of the specialty pharmaceutical company’s stock worth $57,405,000 after purchasing an additional 15,496 shares during the last quarter. UBS Group AG increased its position in ANI Pharmaceuticals by 45.8% during the third quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock worth $54,032,000 after purchasing an additional 185,172 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its position in ANI Pharmaceuticals by 19.3% during the first quarter. Arrowstreet Capital Limited Partnership now owns 564,360 shares of the specialty pharmaceutical company’s stock worth $43,399,000 after purchasing an additional 91,153 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in ANI Pharmaceuticals by 8.9% during the first quarter. Dimensional Fund Advisors LP now owns 531,190 shares of the specialty pharmaceutical company’s stock worth $40,843,000 after purchasing an additional 43,523 shares during the period. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Insider Activity at ANI Pharmaceuticals

In other news, CFO Stephen P. Carey sold 2,850 shares of the company’s stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $81.36, for a total value of $231,876.00. Following the transaction, the chief financial officer directly owned 174,693 shares in the company, valued at approximately $14,213,022.48. This represents a 1.61% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Meredith Cook sold 500 shares of the stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $75.48, for a total transaction of $37,740.00. Following the transaction, the vice president directly owned 74,424 shares of the company’s stock, valued at $5,617,523.52. The trade was a 0.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 18,987 shares of company stock valued at $1,546,405 over the last 90 days. Insiders own 8.10% of the company’s stock.

Analyst Upgrades and Downgrades

ANIP has been the topic of several recent analyst reports. Wall Street Zen lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Canaccord Genuity Group reduced their price target on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a research report on Monday, August 10th. Guggenheim reduced their price target on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a research report on Monday, August 10th. Weiss Ratings cut ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Finally, Zacks Research lowered ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Four research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $105.83.

ANI Pharmaceuticals Stock Up 1.1%

Shares of ANIP opened at $76.87 on Wednesday. The firm has a market cap of $1.77 billion, a P/E ratio of 16.57 and a beta of 0.44. ANI Pharmaceuticals, Inc. has a 12-month low of $70.15 and a 12-month high of $99.50. The company’s 50-day moving average price is $80.65 and its 200 day moving average price is $78.97. The company has a current ratio of 2.91, a quick ratio of 2.41 and a debt-to-equity ratio of 0.99.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, beating analysts’ consensus estimates of $2.04 by $0.17. The company had revenue of $266.04 million for the quarter, compared to analysts’ expectations of $260.13 million. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. ANI Pharmaceuticals’s revenue for the quarter was up 25.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.80 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, sell-side analysts forecast that ANI Pharmaceuticals, Inc. will post 8.03 earnings per share for the current year.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.